Lycorine: From Extraction and Synthesis to Formulation Development—Research Challenges and Advances in Pharmacological Mechanisms and Clinical Translation
Archiv der Pharmazie · 2026
DOI: 10.1002/ardp.70255 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archiv der Pharmazie, 2026. Verfasst von Cong Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, China. Hauptthemen laut MEDLINE: Amaryllidaceae Alkaloids, Phenanthridines, Drug Development, Lycoris. Die Arbeit nennt 116 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Inner Mongolia Major science and technology, Liaoning Provincial Science and Technology Programme Joint Programme (Applied Basic Research Project).
Abstract (Originalsprache)
Lycorine, a natural alkaloid derived from plants of the lycoris genus, has attracted considerable attention in antiviral, antitumor, and anti‐inflammatory research due to its distinctive chemical architecture and broad‐spectrum bioactivities. However, the ongoing refinement of therapeutic strategies and the growing challenge of drug resistance underscore the need for a systematic evaluation of its pharmacological potential and current progress in pharmaceutical development. This review summarizes extraction methodologies and synthetic strategies for lycorine, analyzing existing challenges and potential directions for optimization in its synthesis. Furthermore, recent advances in formulation design and delivery systems utilizing lycorine are highlighted, followed by a focused discussion of its pharmacokinetic profile and multitarget mechanisms of action, with particular emphasis on its anti‐inflammatory, antibacterial, antitumor, antiviral, and antifibrotic activities. Despite its notable therapeutic promise, the clinical translation of lycorine remains limited by complex synthetic routes, incompletely elucidated mechanisms, and relatively slow progress in formulation development. The necessity for continued research into scalable synthesis, mechanistic clarity, and advanced delivery systems is critical to overcome these barriers and unlock the full potential of lycorine in future clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, China.
- School of Life and Health, Dalian University, Dalian, China.
- Dalian Institute of Marine Traditional Chinese Medicine, Dalian, China.
ORCID-Profile: Chungang Zhang
Förderung
- National Natural Science Foundation of China
- Inner Mongolia Major science and technology
- Liaoning Provincial Science and Technology Programme Joint Programme (Applied Basic Research Project)
- Liaoning University of Traditional Chinese Medicine-Natural Science University Key Project
- Liaoning Provincial Department of Education university basic scientific research project reserve project
- National Key Research and Development Program
- Liaoning Province Science and Technology Plan Joint Plan (Natural Science Foundation-Doctoral Research Start-up Project)
- National Basic Research Program of China
Zitieren
APA
Zhang, C., Yu, C., Zhang, C., & Li, J. (2026). Lycorine: From Extraction and Synthesis to Formulation Development—Research Challenges and Advances in Pharmacological Mechanisms and Clinical Translation. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70255
Vancouver
Zhang C, Yu C, Zhang C, Li J. Lycorine: From Extraction and Synthesis to Formulation Development—Research Challenges and Advances in Pharmacological Mechanisms and Clinical Translation. Archiv der Pharmazie. 2026. doi:10.1002/ardp.70255
BibTeX
@article{Zhang2026,
author = {Zhang, Cong and Yu, Chenchen and Zhang, Chungang and Li, Jiahui},
title = {Lycorine: From Extraction and Synthesis to Formulation Development—Research Challenges and Advances in Pharmacological Mechanisms and Clinical Translation},
journal = {Archiv der Pharmazie},
year = {2026},
doi = {10.1002/ardp.70255}
}
EUVIMED